// App-Quantinova.ai

46 : Comparison of Dose Escalation and Co-therapy Intensification between Patients with Rheumatoid Arthritis Initiating Biologic Treatment with Etanercept, Adalimumab and Infliximab

Researchers

Presenter

  • Gilles Boire

Principal Investigators

  • Andrew Chow

  • Kirsten Garces

  • Melanie Poulin-Costello

  • Valery Walker

  • Boulos Haraoui

Medical Centers

  • Universite de Sherbrooke, Sherbrooke, QC, Canada

  • Credit Valley Rheumatology, Mississauga, ON, Canada

  • Optum, Burlington, ON, Canada

  • Institut de Rhumatologie, Montreal, QC, Canada

Locations

  • Canada

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • TNF Receptor Superfamily Member 1B

  • Interferon

Drug/Treatment

  • Adalimumab

  • Infliximab

  • Etanercept

  • CHS-0214

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved